Fingerprint
Dive into the research topics of 'Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or –intolerant chronic phase chronic myeloid leukaemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or –intolerant chronic phase chronic myeloid leukaemia
Martin Hoyle, Gabriel Rogers, Tiffany Moxham, Zulian Liu, Ken Stein
Research output: Contribution to journal › Article › peer-review
29
Citations
(Scopus)